Nasdaq Notifies Jaguar Health of Delisting Due to Bid Price Non-Compliance
JAGX is trading near its 52-week low of $0.56 (15% above the low) on light trading volume (0.1× avg).
Summary
Jaguar Health has received a delisting notice from Nasdaq for failing to maintain the $1.00 minimum bid price. The situation is exacerbated by the company's ineligibility for a compliance period due to recent reverse stock splits, indicating a history of struggles with listing requirements. While the company intends to appeal, this notice poses a severe risk to its public listing, potentially hindering its ability to raise capital and maintain investor confidence. This significant governance issue overshadows recent events, such as the $3 million payment received and the Series O Convertible Preferred Stock dividend, highlighting the company's precarious financial and operational standing.
At the time of this announcement, JAGX was trading at $0.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $0.56 to $15.48. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.